https://pharminent.com/strategic-news-watch/strategic-news-watch-june-25-2026/ 2026-06-25T16:17:32Z Pharminent en Strategic News Watch • June 25, 2026 2026-06-25T16:17:22Z Blog https://pharminent.com/regenerons-cemdisiran-earns-fda-priority-review-for-gmg/ 2026-06-25T13:12:06Z Pharminent en Regeneron's Cemdisiran Earns FDA Priority Review for gMG 2026-06-25T13:12:06Z Blog https://pharminent.com/msds-keytruda-padcev-combo-secures-ec-approval-for-mibc/ 2026-06-25T15:26:26Z Pharminent en MSD's Keytruda-Padcev combo secures EC approval for MIBC 2026-06-25T09:46:39Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-june-24-2026/ 2026-06-24T20:52:32Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • June 24, 2026 2026-06-24T20:52:30Z Blog https://pharminent.com/sk-pharmteco-launches-skyvec-viral-vector-platform-for-gene-therapy/ 2026-06-24T18:54:42Z Pharminent en SK pharmteco Launches SKyvec Viral Vector Platform for Gene Therapy 2026-06-24T18:54:42Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-june-24-2026/ 2026-06-24T18:26:41Z Pharminent en Manufacturing Intelligence • Weekly Digest • June 24, 2026 2026-06-24T18:26:39Z Blog https://pharminent.com/novartis-strikes-up-to-1-9-billion-oncology-discovery-collaboration-with-antares-therapeutics/ 2026-06-24T17:11:57Z Pharminent en Novartis Strikes Up-to-$1.9 Billion Oncology Discovery Collaboration With Antares Therapeutics 2026-06-24T16:33:42Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-24-2026/ 2026-06-24T16:00:27Z Pharminent en Strategic News Watch • June 24, 2026 2026-06-24T16:00:25Z Blog https://pharminent.com/lundbeck-to-present-new-vyepti-and-bocunebart-data-at-ean-2026/ 2026-06-24T14:29:32Z Pharminent en Lundbeck to present new Vyepti and bocunebart data at EAN 2026 2026-06-24T11:08:29Z Blog https://pharminent.com/boehringer-and-combotope-partner-for-cancer-antibodies/ 2026-06-24T14:30:26Z Pharminent en Boehringer and Combotope partner for cancer antibodies 2026-06-24T10:03:11Z Blog https://pharminent.com/efpia-report-adds-to-pressures-on-eu-drug-pricing-policy/ 2026-06-24T14:24:53Z Pharminent en EFPIA report adds to pressures on EU drug pricing policy 2026-06-24T08:34:20Z Blog https://pharminent.com/carsgens-satri-cel-wins-world-first-car-t-approval-for-solid-tumor/ 2026-06-23T20:42:31Z Pharminent en CARsgen's Satri-cel Wins World-First CAR-T Approval for Solid Tumor 2026-06-23T20:39:12Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-june-23-2026/ 2026-06-23T20:22:00Z Pharminent en Oncology Intelligence Digest • June 23, 2026 2026-06-23T20:21:58Z Blog https://pharminent.com/pfizer-drug-acquired-in-seagen-deal-disappoints-in-lung-cancer-study/ 2026-06-24T14:27:11Z Pharminent en Pfizer drug acquired in Seagen deal disappoints in lung cancer study 2026-06-23T16:06:00Z Blog https://pharminent.com/lilly-and-astellas-circle-sangamo-assets-as-the-biotech-files-for-bankruptcy/ 2026-06-23T16:03:44Z Pharminent en Lilly and Astellas Circle Sangamo Assets as the Biotech Files for Bankruptcy 2026-06-23T16:03:40Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-23-2026/ 2026-06-23T15:44:59Z Pharminent en Strategic News Watch • June 23, 2026 2026-06-23T15:44:57Z Blog